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Acute promyelocytic leukemia (APL) is a hematopoietic malignant disease 
characterized by the chromosomal translocation t(15;17), resulting in the fusion of the 
PML-RARA gene.  Here, 47 t(15;17) APL samples were analyzed with high-density 
single-nucleotide polymorphism microarray (50K and 250K SNP-chips) using the new 
algorithm AsCNAR (allele-specific copy-number analysis using anonymous references).  
Copy-number-neutral loss of heterozygosity (CNN-LOH) was identified at chromosome 
10q (3 cases), 11p (3 cases) and 19q (1 case).  Twenty-eight samples (60%) did not 
have an obvious alteration (normal-copy-number [NC] group).  Nineteen samples 
(40%) showed either one or more genomic abnormalities: 8 samples (17%) had trisomy 
8 either with or without an additional duplication, deletion, or CNN-LOH (+8 group); 
and 11 samples (23%) had genomic abnormalities without trisomy 8 (other 
abnormalities group).  These chromosomal abnormalities were acquired somatic 
mutations.  Interestingly, FLT3-ITD mutations (11/47 cases) only occurred in the 
group with no genomic alteration (NC group).  Taken together, these results suggest 
that the pathway of development of APL differs in each group: FLT3-ITD, trisomy 8, 
and other genomic changes.  Here, we showed for the first time hidden abnormalities 




Acute promyelocytic leukemia (APL) is a hematopoietic malignant disease 
characterized by the chromosomal translocation t(15;17), resulting in the fusion of the 
promyelocytic leukemia (PML) gene and retinoic acid receptor α (RARA) gene 
(PML-RARA).1,2  The fusion product of PML-RARα homodimerizes, binds to DNA, 
and works as a transcriptional repressor together with co-repressors including histone 
deacetylase.3  Therefore, re-activation of RARα-dependent transcription is one of the 
major strategies to treat APL patients.  In fact, all-trans retinoic acid (ATRA), which 
binds to RARα and leads to the activation of the transcription factor, is a highly 
effective compound for the induction of remission of APL patients.4,5 
 Transgenic mice revealed that PML-RARα is necessary but not sufficient for 
the development of APL.6,7  APL occurred in these mice only after a long latency (8.5 
to 12 months) and penetrance was 15% to 30%.6,7  These findings suggest that 
additional genetic mutations are also required for the development of APL.  Candidate 
genes include the tyrosine kinase receptor gene, FLT3 and the oncogene, RAS.  
Activating FLT3 mutations occur in about 30-35% APL samples;8,9 and NRAS and 
KRAS mutations are found in 4-5% and 5-10% of APL samples, respectively.9,10  
Interestingly, transgenic mice co-expressing PML-RARα and either FLT3W51 
(constitutively activated form of murine FLT3), FLT3-ITD or K-Ras (K12D) develop 
APL with a short latency and a high penetrance.11-14 
Comparative genomic hybridization (CGH) is one of the genome-wide 
screening methods to identify chromosomal abnormalities.  However, CGH analysis 
cannot detect copy-number-neutral loss of heterozygosity (CNN-LOH).  
Single-nucleotide polymorphism microarray (SNP-chip) is a powerful method to 
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examine genomic alterations including small copy-number changes and/or CNN-LOH 
in several cancers.15-17  SNP-chip analysis has been used for chronic lymphocytic 
leukemia (CLL),18,19 childhood acute lymphoblastic leukemia (ALL),20,21 acute myeloid 
leukemia (AML)22-26 and AML with normal karyotype (Gorletta et al.27 and  Akagi et 
al. submitted). 
In the present study, we focused on t(15;17) APL and examined whether 
additional genomic alterations could be found to subcategorize this disease on the basis 
of genomic status.  The use of CNAG (copy-number analysis for Affymetrix 
GeneChips) program15 and a new algorithm AsCNAR (allele-specific copy-number 
analysis using anonymous references)17 provide a highly sensitive technique to detect 
CNN-LOH, as well as, copy-number changes in APL. 
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Materials and methods 
Patient samples 
DNA from the bone marrow of 47 anonymized cases of t(15;17) APL at diagnosis, as 
well as, 7 complete remission bone marrow samples were examined.  Sample 
information including the form of PML-RARα (long, short or variant), gender, age,  
white blood cell counts (WBC), blast percentage in the bone marrow, mutational status 
of the FLT3 gene, FLT3-ITD level and karyotype are shown in Table 1. 
 
High-density SNP-chip analysis 
Genomic DNA was isolated from bone marrow samples from t(15;17) APL patients at 
diagnosis and complete remission, as well as, APL cell lines NB4 and PL-21.  The 
DNA was subjected to GeneChip Human mapping 50 K or 250 K microarray (SNP-chip, 
Affymetrix, Santa Clara, CA, USA) as described previously.15,17  Hybridization, 
washing and signal detection were performed on GeneChip Fluidics Station 400 and 
GeneChip scanner 3000 according to the manufacturer’s protocols (Affymetrix). 
Microarray data were analyzed for determination of both total and allelic-specific 
copy-number (AsCN) using the CNAG program as previously described15, 17 with minor 
modifications, where the status of copy-numbers as well as CNN-LOH at each SNP was 
inferred using the algorithms based on Hidden Markov Models15, 17  For clustering of 
AML samples with regard to the status of copy-number changes, as well as, CNN-LOH, 
GNAGraph software was used.21  Size, position and location of genes were identified 
with UCSC Genome Browser <http://genome.ucsc.edu/>.  Germline copy-number 
changes previously described as copy-number variant at Database of Genomic Variants 




Determination of SNP sequences in cases of CNN-LOH and FLT3 mutations 
To validate CNN-LOH, 2 SNP sequences (rs10500648 and rs7937815) in chromosome 
11p of case #39 at diagnosis and complete remission, and 6 SNP sequences 
(rs10491032, rs363221, rs2099803, rs2104543, rs7075893 and rs7918018) in 
chromosome 10q of case #18 at diagnosis were determined.   The genomic region of 
each SNP site was amplified by genomic PCR using specific primers (Supplemental 
Table 1), and PCR products were purified and sequenced.  For determinations of 
FLT3-TKD and FLT3-ITD mutations, genomic PCR was performed as described 
previously.28  
 
Cell culture, mRNA isolation and quantitative real-time PCR 
APL cell lines, NB4 and PL-21 were cultured in RPMI1640 medium (Invitrogen, 
Carlsbad, CA, USA) with 10% FBS (Atlanta Biologicals, Inc., Lawrenceville, GA, 
USA).  Total RNA was isolated from these cells and case #48 bone marrow sample at 
diagnosis using RNeasy kit (QIAGEN, Valencia, CA, USA), and 1μg of total RNA was 
converted into cDNA by reverse transcription with Superscript III (Invitrogen).  Gene 
expression of c-Myc mRNA was quantified with real-time quantitative PCR (iCycler, 
Bio-Rad, Hercules, CA, USA) using Sybr Green.  β-actin was used as control. 
Copy-number of chromosome 11p15.4 in case #39, 10q24.31 in case #18, the 
MYC gene in cases #2, #18 and #65 and the ERG gene in case #43 were determined by 
quantitative real-time PCR (Bio-Rad) using Sybr Green.  Region on chromosome 2p21 
was used as control.21  Copy-number of the 2p21 region was normal as determined by 
SNP-chip analysis in these samples.  The delta threshold cycle value (ΔCt) was 
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calculated from the given Ct value by the formula ΔCt = (Ct sample - Ct control).  The 





SNP-chip analysis of t(15;17) APL samples 
 We examined the genomic changes in 47 samples of t(15;17) APL using 50 K 
and 250K SNP-chip analyses.  A total of 28 patients (60%) showed no detectable 
genomic abnormalities [normal-copy-number (NC) group].  In contrast, 19 patients 
(40%) had one or more genomic abnormalities: 8 patients (17%) had trisomy 8 or 
duplication on chromosome 8 in the region of the MYC gene either with or without 
other genomic abnormalities (+8 group); and 11 patients (23%) had genomic 
abnormalities without trisomy 8 (other abnormalities group) (Figure 1 and Table 2).  
One case (case #65, 2%) had 4 chromosomally altered regions; 2 cases (4%; 
#39 and #58) had 3 chromosomally altered regions; 8 cases (17%; #2, #50, #3, #18, #13, 
#37, #19, and #21) had 2 chromosomally altered regions; and 8 cases (17%; #38, #60, 
#66, #20, #4, #57, #43, and #52) had 1 chromosomally altered region.  Importantly, 6 
patients (13%) had CNN-LOH. 
 
Validation of SNP-chip analysis. 
As proof of principal, we validated SNP-chip results using quantitative 
genomic real-time PCR (QG RT-PCR) and nucleotide sequencing of SNP sites.  Case 
#65 had a duplicated region at chromosome 8, and this region contained the MYC gene 
(Figure 2A).  QG RT-PCR showed that levels of the MYC copy-number were about 
2-fold higher than normal genomic DNA (Figure 2B).  Other copy-number changes 
including duplication of the MYC gene in cases #2 and #18, and duplication of the ERG 
gene in case #43 were also confirmed by QG RT-PCR (data not shown).  
Next, we validate CNN-LOH detected by SNP-chip analysis (Figure 3).  If a 
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chromosome has LOH, SNP sequences in this region should have homozygosity at 
diagnosis but heterozygosity at complete remission.  Therefore, we examined two 
independent SNP sequences in case #39 on chromosome 11p in the CNN-LOH region 
using diagnosis and complete remission samples.  Two SNP sites (rs10500648 and 
rs7937815) clearly showed a single signal at diagnosis (homozygosity); whereas, the 
sites were double signal at complete remission (heterozygosity) (Figure 3B).  These 
result demonstrated that this region had LOH.  Next, we determined copy-number of 
the region to exclude the possibility of a hemizygous deletion.  As shown in Figure 3C, 
level of DNA at the 11p15.4 region of case #39 at diagnosis was almost the same as 
level of the complete remission sample, indicating that this region had a 
normal-copy-number and the region represented CNN-LOH.  CNN-LOH region of 
case #18 was also validated by SNP sequencing and QG RT-PCR (Supplemental Figure 
1).  Taken together, these results indicated that SNP-chip analysis clearly reflected real 
chromosomal abnormalities. 
 
Copy-number changes in t(15;17) APL samples 
 As shown in Table 2, several copy-number changes were detected by SNP-chip 
analysis.  Deletions were found in 7 cases (15%) including case #65 (4q28.1, 1.33 Mb; 
7q21.11-q21.12, 1.03 Mb; and 9q12-q31.3, 47.27 Mb), case #2 (10q21.2-q21.3, 5.55 
Mb), case #50 (6p25.1-p24.3, 2.51 Mb), case #37 (1q42.2, 0.02 Mb), case #19 
(12p13.31 - p11.22, 22.49 Mb; and 13q14.2 - q14.3, 0.88 Mb), case #21 (7q11.21 - 
q-terminal, 97.03 Mb), and case #58 (17p-terminal - p11.2, 21.44 Mb).   Of note, 
deleted region at 12p of case #19 and 17p of case #58 contained the ETV6/TEL and 
TP53 genes, respectively. 
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Duplications were found in 7 cases (15%) including case #65 (8q24.13-q24.22, 
9.48 Mb), case #13 (13q21.1- q-terminal, 57.27 Mb; and 15q22.2 - q-terminal, 42.94 
Mb), case #57 (9q22.32, 0.27 Mb), case #37 (18p11.31 - p11.23, 0.46 Mb), case #21 
(1q21 - q-terminal, 102.63 Mb), case #43 (21q22.12 - q-terminal, 10.69 Mb), and case 
#58 (15q24.1 – q-terminal, 27.97 Mb; and 17p11.2-q21.1, 14.05 Mb).  Duplicated 
region at 21q of case #43 and at 17p of case #58 included the ERG and ERBB2 genes, 
respectively.  Importantly, duplicated region at 8q of case #65 contained the MYC gene 
(Figure 2A).  Seven cases had trisomy 8, and one of the candidate genes on 
chromosome 8 is the MYC gene; therefore, we classified case #65 within the +8 group. 
Of note, NB4 APL cell line had amplification of the MYC gene region 
(8q24.21), whereas PL-21 APL cell line showed duplication of the region (Supplemental 
Figure 2A).  We compared levels of c-Myc mRNA in these cell lines, and found that 
NB4 cells had about 6-fold higher expression of c-Myc than did PL-21 cells 
(Supplemental Figure 2B).  This result indicated that copy-number change was 
associated with mRNA levels of the target gene. 
 
CNN-LOH in t(15;17) samples 
Several cases had the same chromosomal region involved in CNN-LOH.  
Chromosome 10q CNN-LOH was found in 3 cases (6%) including case #18 
(10q22.2-q-terminal), case #39 (10q21.1-q-terminal) and case #66 (10q22.2-q-terminal) 
(Figure 1 and Supplemental Figure 3A).  This region included the tyrosine kinase 
receptor gene FGFR2 and the tumor suppressor gene PTEN (Table 2).  Cases #3, #20 
and #39 had CNN-LOH on 11p-terminal - p11.12, 11p-terminal - p11.12, and 
11p-terminal - p14.1, respectively; and the common region was 28.7 Mb (Figure 1 and 
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Supplemental Figure 3B) containing the tumor suppressor genes WT1 and CDKN1C, 
and the oncogene HRAS (Table 2).  CNN-LOH of 19q13.2 - q-terminal (17.3 Mb) 
occurred in one case (#4, Table 2). 
 
Comparison of chromosomal changes between diagnosis and complete remission 
samples 
 To assess whether chromosomal alterations detected by SNP-chip analysis 
were acquired abnormalities, germline mutations or copy-number variants, we 
compared chromosomal changes between diagnosis and complete remission (CR) 
samples in the same patients.  CR samples of cases #2, #3, #18, #19, #38, #39 and #50 
were available, and these CR samples were subjected to SNP-chip analysis.  As shown 
in Figure 4, trisomy 8 of case #2 and CNN-LOH of case #18 at diagnosis were not 
present in the samples obtained at CR.  Other alterations including trisomy 8 (cases #3, 
#18, #38, #39 and #50), CNN-LOH at chromosomes 10 (case #39) and 11 (cases #3 and 
#39), and deletions (cases #2, #19, and #50) also were not present at CR (Supplemental 
Figure 4).  Taken together, these results showed that chromosomal alterations detected 
by SNP-chip analysis were acquired somatic changes.   
 
Relationship between genomic abnormalities and FLT3 mutations 
 Finally, we compared genomic abnormalities and FLT3 status.  Twenty-four 
samples (51%) had wild-type FLT3; whereas 12 samples (26%) had FLT3-TKD 
mutation (aspartic acid at codon 835, D835) and another 11 samples (23%) had 
FLT3-ITD form.  Interestingly, all 11 samples with FLT3-ITD were found only in the 
normal-copy-number (NC) group (Tables 1 and 3).  One sample in the trisomy 8 group 
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had a FLT3-TKD mutation.  Samples in the “other abnormalities” group did not have 
FLT3-ITD; and 6 samples in NC group and 5 samples in the “other abnormalities” 
group had a FLT3-TKD mutation.  These results suggested that the pathway of 
development of APL differs in each group; in a mutually exclusive fashion, FLT3-ITD, 




 Our genome-wide SNP-chip analysis showed that 40% of t(15;17) APL 
samples had one or more genomic abnormalities including deletions, duplications 
and/or CNN-LOH.  Since the PML-RARα fusion protein is probably not sufficient to 
cause APL in murine model systems, the additional genetic changes that we found, may 
be necessary to cause the leukemia. 
 Our analysis revealed that 6 samples (13%) of t(15;17) APL samples had 
CNN-LOH.  Previously, we analyzed AML with normal karyotype samples and found 
that 32% of samples had CNN-LOH (Akagi et al, submitted); and other investigators 
also demonstrated CNN-LOH in AML samples at a frequency of 15 – 20%.22-25,27  Of 
interest, about 40% of relapse AML had CNN-LOH.26  CNN-LOH in t(15;17) APL is 
about half as frequent as the other AMLs.  Two CNN-LOH regions occurred in 
multiple samples: chromosomes 10q (58.2 Mb, 3 cases) and 11p (28.7 Mb, 3 cases).  
Of note, case #39 had both 10q and 11p CNN-LOHs, suggesting that 10q and 11p might 
contain novel APL-related gene(s).  Furthermore, 3 APL cases (#66, #20 and #4) had 
CNN-LOH, and these 3 cases did not contain additional chromosomal alterations.  
CNN-LOH is a genomic abnormality that normally cannot be detected by conventional 
cytogenetic analysis.  These regions usually contain a mutation of a key gene.  For 
example, a constitutively active form of either JAK2 V617F mutant, FLT3-ITD, 
AML1/RUNX1 frameshift, and/or mutations of WT1 and NPM1 were found in 
CNN-LOH regions in AML.22-25  CNN-LOH regions identified in this study contains 
genes coding for several tyrosine kinase and/or tumor suppressors.  Further studies are 
required to identify the key dysregulated gene(s) in these regions.  In addition to 
CNN-LOH, we also found several copy-number changes which may be sites containing 
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novel disease-related genomic regions in t(15;17) APL.  Although we cannot rule-out 
copy-number variants (CNVs) at several sites, we think it is unlikely.  We had 7 
genomic DNA at complete remission samples and confirmed for each that the 
chromosomal changes were only in the leukemia cells.  Furthermore, for each of these 
sites, we interrogated a collated library of CNVs (Database of Genomic Variants and 
UCSC Genome Browser) to assure that these regions were not known CNVs. 
FLT3 is a tyrosine kinase receptor involved in normal hematopoiesis; and 
mutations of the gene often occur in AML.  Incidence of FLT3-ITD and FLT3-TKD 
was 23% and 26% in our samples, respectively.  Experiments have shown that 
FLT3-ITD and FLT3-TKD have differences in their downstream signaling.29-31  
Interestingly, bone marrow transplantation in mice showed that FLT3-ITD induced an 
oligoclonal myeloproliferative disease;29 whereas FLT3-TKD produced an oligoclonal 
lymphoid disorder with a long latency.30  Furthermore, only FLT3-ITD caused 
activation of STAT5 and repression of C/EBPα and PU.1.30,31 
Here, t(15;17) APL samples were divided into three groups based on genomic 
status detected by SNP-chip analysis: normal-copy-number group (NC group, 28 
samples); trisomy 8 group (+8 group, 8 samples); and other abnormalities group  (11 
samples).   Notably, our subclassifications did reveal an interesting relationship 
between genomic status and FLT3 mutation.  Eleven samples of NC group (39% of the 
NC group samples) had FLT3-ITD, while no FLT3-ITD occurred in samples from the 
other 2 groups.  In contrast, one good candidate gene in the +8 cohort is the oncogene 
MYC.  In fact, case #65 had duplication localized to 8q24.13-q24.22 which included 
the MYC gene.  Previous karyotype analysis showed that the PL-21 cell line, which 
was established from an APL patient, had a polyploidy male karyotype with 13q+ 
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chromosome; but a translocation between chromosome 15 and 17 was not identified.40  
NB4 cells are cytogenetically very complex, with a hypotetraploid karyotype and 
multiple chromosomal alterations.32,33  Our SNP-chip analysis of NB4 cells also 
showed ploidy=3.67, indicating that the karyotype is hypotetraploid.  Of interest, NB4 
cells have amplification of the MYC gene.  Importantly, expression of c-Myc mRNA is 
stimulated by FLT3-ITD;34,35 and AML samples with FLT3-ITD have increased 
expression of c-Myc mRNA compared with normal bone marrow.36  These data 
indicate that the MYC gene may be dysregulated by either copy-number change or 
FLT3-ITD as a secondary abnormality to enhance the development of APL.  Of course, 
our sample population is small; therefore, additional studies are needed to confirm these 
findings. 
Our APL cohort, “other abnormalities” group has neither FLT3-ITD nor 
trisomy 8, but have several other genomic changes including deletion of ETV6/TEL 
(case #19) and duplication of ERG (case #43).  ETV6/TEL is a transcriptional repressor, 
and about 30% of AML patients have loss of expression of ETV6/TEL protein.37,38  In 
addition, mutation of the ETV6/TEL gene occurs in about 2% of AML samples; and 
these mutants behaved in a dominant-negative fashion.38  ERG is a member of the ETS 
family of transcription factors and is a proto-oncogene.  Overexpression of ERG 
predicts a worse outcome in AML with normal karyotype.39  Taken together, our 
observed copy-number changes in these regions may be involved in development of 
APL. 
Our findings extend those of Le Beau et al13 who recently reported elegant 
models of APL using transgenic mice coexpressing PML-RARα and either BCL2, IL3, 
activated IL3R or activated murine FLT3 (FLT3W51).  PML-RARα/BCL2 mice 
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developed leukemia; and these cells had a complex karyotype including trisomy 15 
(100% of these mice), where the oncogene MYC is located.  In contrast, 
PML-RARα/FLT3W51 mice develop leukemia, and these cells had normal karyotype 
except for trisomy of either chromosomes 8 (29%), 10 (43%), or 15 (43%); and 
monosomy X (86%).  These models suggest that different cooperating events are 
involved in the development murine APL.  Taken together, these findings strongly 
suggest that the pathway of development of APL differs in each of our cohorts; 
FLT3-ITD, MYC, and unknown factor(s) are involved in the development of APL; and 
these finding should facilitate the screening for novel therapeutic targets in each case.   
Further studies in a larger cohort of patients will begin to stratify prognostically 
the APL patients in relation to the genomic changes of their leukemic cells; and new 
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Figure 1.  Summary of genomic abnormalities in t(15;17) APL samples.  Genomic 
DNA of 47 t(15;17) APL samples were subjected to SNP-chip analysis; and genomic 
abnormalities are summarized.  Color boxes are used to denotes the type and size of 
abnormalities: Pink (copy-number-neutral loss of heterozygosity; CNN-LOH); green 
(deletion); and red (duplication including trisomy).  A total of 28 patients (60%) 
showed no detectable genomic abnormalities (data not shown).  In contrast, 19 patients 
(40%) had one or more genomic abnormalities: trisomy 8 or duplication of the MYC 
gene region either with or without genomic abnormalities was found in 8 patients (17%, 
referred as “+8”) and 11 patients (23%, referred as “other abnormalities”) had genomic 
abnormalities without trisomy 8.  Six patients (13%) had CNN-LOH; and one sample 
in +8 group and 5 samples in other abnormalities group had FLT3 point mutations 
which are shown by their amino acid change at codon 835 from D (aspartic acid) to 
either Y (tyrosine), E (glutamic acid) or H (histidine). 
 
Figure 2.  Validation of copy-number change in case #65.  (A) SNP-chip data of 
chromosome 8 in case #65.  Red dots are SNP sites as probes and indicate total 
copy-number (CN).  Blue line is an average of the copy-number and shows gene 
dosage.  Green bars are heterozygous (hetero) SNP calls.  Red and green lines show 
allele-specific copy-number (AsCN).  (B) Duplication of the MYC gene region in case 
#65.  Copy-number of the MYC gene in case #65 was compared to normal genomic 
DNA with quantitative genomic real-time PCR.  Level of the copy-number was 
determined as a ratio between the MYC gene and the reference genomic region 2p21.  




Figure 3.  Validation of CNN-LOH in case #39.  (A) SNP-chip data of 
chromosome 11 in case #39.  The samples had CNN-LOH on chromosome 11 
(11p-terminal – p14.1, 28.7 Mb).  (B) Determination of SNP sequence in 11p 
CNN-LOH region in case #39.  Two SNP sites (rs10500648 and rs7937815) were 
sequenced.  Both SNP sites showed heterozygosity in the complete remission sample; 
whereas they showed homozygosity in the diagnosis sample.  (C) Determination of 
copy-number in the 11p15.4 region.  Copy-number of 11p15.4 (CNN-LOH region) in 
case #39 at diagnosis was compared to complete remission (CR) sample with 
quantitative genomic real-time PCR.  Levels of the copy-number were determined as a 
ratio between 11p15.4 and the reference genomic DNA, 2p21.  Results represent the 
mean of 3 experiments ± SD. 
 
Figure 4.  Comparison of chromosomal changes between diagnosis and complete 
remission samples.  (A) Trisomy 8 in case #2.  Case #2 had trisomy 8 at diagnosis; 
whereas chromosome 8 was 2n at complete remission (CR).  (B)  CNN-LOH in case 
#18.  Case #18 had CNN-LOH in chromosome 10 (10q22.2 – q-terminal, 58.2 Mb); 
and the alteration was not present in the matched CR sample. 
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Legends for Supplemental Figures 
 
Supplemental Figure 1.  Validation of CNN-LOH in case #18.  (A) Determination 
of SNP sequence in 10q CNN-LOH region.  Six independent SNP sites (rs10491032, 
rs363221, rs2099803, rs2104543, rs7075893 and rs7918018) were sequenced.  All 6 
SNP sites showed only a single nucleotide; no SNP sites showed heterozygosity 
consistent with CNN-LOH.  (B) Determination of copy-number in the 10q region.  
Copy-number of 10q24.31 (CNN-LOH region) in case #18 was compared to DNA from 
normal white blood cells using quantitative genomic real-time PCR.  Levels of the 
copy-number were determined as a ratio between 10q24.31 and the reference genomic 
DNA, 2p21.  Results represent the mean of 3 experiments ± SD. 
 
Supplemental Figure 2.  Expression of c-Myc mRNA in NB4 and PL-21 APL cell 
lines.  (A) SNP-chip results of NB4 and PL-21 APL cell lines, as well as, bone marrow 
sample of case #48.  NB4 cells had amplification of 8q24.21 region, and this region 
included the MYC gene.  On the other hand, the region had a duplication in the PL-21 
cells and had a normal copy-number in case #48.  (B) Expression of c-Myc mRNA.  
Levels of c-Myc mRNA in cells from NB4, PL-21, and case #48 were determined by 
quantitative real-time PCR.  Results represent the mean of 3 experiments ± SD. 
 
 
Supplemental Figure 3.  Chromosomal region of CNN-LOH in t(15;17) APL 
samples.  When one allele copy-number  (red-line) increases and the other allele 
copy-number  (green-line) decreases, the region has loss of heterozygosity; and if the 
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region has normal-copy-number, the sample has copy-number-neutral loss of 
heterozygosity (CNN-LOH).  (A) Chromosome 10q CNN-LOH was found in three 
cases including #18 (10q22.2 - q-terminal, 58.2 Mb), #39 (10q21.1 - q-terminal, 75.7 
Mb) and #66 (10q22.2 - q-terminal, 59.0 Mb).  (B) Chromosome 11p CNN-LOH was 
noted in three cases including #3 (11p-terminal - p11.12, 47.9 Mb), #20 (11p-terminal - 
p11.12, 47.4 Mb), and #39 (11p-terminal - p14.1, 28.7 Mb).  Chromosomal and 
physical localization, size, as well as, genes in the regions are described in Table 2. 
 
Supplemental Figure 4.  Comparison of chromosomal changes between diagnosis 
and complete remission samples.  Chromosomal status of DNA of matched complete 
remission samples of cases #2, #3, #18, #19, #38, #39 and #50 were compared to 
samples obtained at diagnosis.  Chromosomal alterations including copy-number 
changes and CNN-LOH were not present in the complete remission samples.  Pink, 
green, and red boxes indicate CNN-LOH (copy-number-neutral loss of heterozygosity), 
deletion, and duplication including trisomy, respectively.  Abbreviations: D, diagnosis; 
C, complete remission. 
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Table 1. Baseline clinical characteristic of 47 t(15;17) APL patients. 
    
PML-RARα 
        FLT3 FLT3-ITD   
Group Case # isoform Sex Age WBC (x 106/L) 
Blast 
(%) 
D835 ITD Level (%) Chromosome 




































































7 S F 31 120000 95 - + 42 46,XX,t(15;17)(q22;q12) 
 




14 S M 9 27980 80 - + 40 46,XY,t(15;17)(q22;q21) 
 
17 S F 47 51100 98 - + 24 46,XX,t(15;17)(q22;q21) 
 
29 S M 75 1500 88 - + 35 ND, RT-PCR(+) 
 
63 S F 57 9700 96 - + 42 46,XX,t(15;17)(q22;q21) 
 
64 S M 28 24800 90 - + 57 46,XY,t(15;17)(q22;q21) [25/26] 
          
46,XY[1/26] 
 
6 L F 37 29500 93 - + 32 ND, RT-PCR(+) 
 
42 L F 24 1200 87 - + 4 46,XX,t(15;17)(q22;q21) 
 
51 L M 51 45400 78 - + 47 46,XY,t(15;17)(q21;q12) 
  62 L F 46 45000 89 - + 42 46,XX,t(15;17) (q22;q21) 
















60 L M 22 9900 90 +H - 
 
46,XY,t(15;17)(q22;q21) [16/21] 
          
47XY,+8,t(15;17) (q22;q21) [4/21] 
          
46,XY [1/21] 
 




39 L M 38 1000 51 - - 
 
47,XY,+8,t(15;17)(q22;q21) 
  18 L M 23 18100 94 - -  ND, RT-PCR(+) 






































52 L M 54 8600 82 - - 
 
46,XY,t(15;17)(q21;q12) [19/20] 
          
47,XY, +21, t(15;17)(q21;q12) [1/20] 
 




           
 
     46,XX [3/26] 
Chromosomal translocation of t(15;17) was determined by karyotype studies and/or RT-PCR analysis specific for PML-RARα 
fusion products.  Three types of PML-RARα (long, short and variant) are shown as L, S and V, respectively.  The recorded 
number of white blood cells (WBC) and bone marrow blast percents were obtained at diagnosis.  Mutations of FLT3 were 
either tyrosine kinase domain (TKD) at codon 835 or internal tandem repeat (ITD).  The APL samples are divided into three 
groups based on SNP-chip analysis: normal-copy-number (CN), trisomy 8 including duplication of the MYC gene region (+8), 
and other abnormalities (other). 
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Table 2. Chromosomal alterations in t(15;17) APL samples 
        Physical localization Size   
Group Case #  Status Location Proximal Distal (Mb) Gene(s) in the region 
+8 65 Del 4q28.1 125190507 126521903 1.33  KIAA1223  
  
Del 7q21.11-q21.12 85414972 86445002 1.03  GRM3, KIAA1324L , and DMTF1 
  
Dup 8q24.13-q24.22 122607785 132092760 9.48  > 10 genes including MYC 
 
  Del 9q12-q31.3 64207745 111479523 47.27  > 10 genes 
 
38 Tri Trisomy 8 - - - - 
 
2 Tri Trisomy 8 - - - - 
 
  Del 10q21.2-q21.3 62496958 68046104 5.55 >10 genes 
 
50 Del 6p25.1-p24.3 5545437 8054930 2.51 > 10 genes 
  
Tri Trisomy 8 - - - - 
 
60 Tri Trisomy 8 - - - - 
 
3 Tri Trisomy 8 - - - - 
 
  CNN-LOH 11p-ter.-p11.12 1,938,894 49,879,899 47.9 > 10 genes including WT1, CDKN1C and HRAS 
 
39 Tri Trisomy 8 - - - - 
  
CNN-LOH 10q21.1-q-ter. 59,576,047 135,228,726 75.7 > 10 genes including PTEN and FGFR2 
 
  CNN-LOH 11p-ter.-p14.1 1,938,894 30,627,880 28.7 > 10 genes including CDKN1C and HRAS 
 
18 Tri Trisomy 8 - - - - 
    CNN-LOH 10q22.2-q-ter. 76,995,152 135,228,726 58.2 > 10 genes including PTEN and FGFR2 
Other 66 CNN-LOH 10q22.2-q-ter. 76,289,513 135,295,604 59.0  > 10 genes including PTEN and FGFR2 
 
20 CNN-LOH 11p-ter.-p11.12 1,938,894 49,330,228 47.4 > 10 genes including WT1, CDKN1C and HRAS 
 




  Dup 15q22.2 - q-ter. 57244668 100182183 42.94 > 10 genes including PML 
 
4 CNN-LOH 19q13.2 - q-ter. 46,160,099 63,437,743 17.3 > 10 genes 
 
37 Del 1q42.2 227843862 227867765 0.02 EGLN1 
 
  Dup 18p11.31 - p11.23 7,192,739 7,657,575 0.46 PTPRM 
 
57 Dup 9q22.32 94435025 94710006 0.27  FBP2, FBP1, and C9orf3 
 
19 Del 12p13.31 - p11.22 6755671 29248257 22.49 > 10 genes including ETV6 and CDKN1B  
 
  Del 13q14.2 - q14.3 49630676 50510777 0.88 FAM10A4, DLEU7, FLJ11712, and GUCY1B2 
 
21 Dup 1q21 - q-ter. 142487224 245120412 102.63 > 10 genes 
 
  Del 7q11.21 - q-ter. 61522282 158554645 97.03 > 10 genes  
 
43 Dup 21q22.12 - q-ter. 36234195 46924583 10.69 >10 genes including ERG 
 
52 Tri Trisomy 21 - - - - 
 
58 Dup 15q24.1 – q-ter. 72224840 100192115 27.97  > 10 genes 
  
Del 17p-ter. - p11.2 18901 21459693 21.44  > 10 genes including TP53 
    Dup 17p11.2 - q21.1 21491135 35542587 14.05  > 10 genes including NF1 and ERBB2 
Physical localization, size (Mb), and gene(s) at the chromosomal regions were obtained from UCSC Genome Browser.  If 
known gene(s) in the chromosomal regions are less than 10, all gene names are displayed.  Abbreviations: Del, deletion; Dup, 
duplication; Tri, trisomy; ter, terminal; CNN-LOH, copy-number-neutral loss of heterozygosity.  Copy number changes as 
previously described as copy number variant at Database of Genomic Variants <http://projects.tcag.ca/variation/> and UCSC 
Genome Browser <http://genome.ucsc.edu/> were excluded. 
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Table 3.  Relationship between chromosomal abnormality and FLT3 mutations 
Group 
NC +8 other Total 
  28 (60%) 8 (17%) 11 (23%) 47 (100%) 
FLT3 WT 11 7 6 24 (51%) 
FLT3 TKD 6 1 5 12 (26%) 
FLT3 ITD 11 0 0 11 (23%) 
Mutational status of the FLT3 gene is shown.  Abbreviations: NC, normal-copy-number; +8, trisomy 8 or duplication of the 
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